Dr Yao (WHO-CI) Dr N’Guessan-Irié (DPM)

Slides:

Advertisements

Similar presentations

Chronic Medication Service (CMS). Programme Introduction Pharmaceutical Care Planning - Ray ePharmacy Programme – Dawn, IM & T Workshops – Niall, Michelle,

Advertisements

Sevene E, Mariano A, Mola D Faculty of Medicine / Ministry of Health Pretoria, September 2004 PHARMACOVIGILANCE SYSTEM - MOZAMBIQUE INTRODUCING PV INTO.

CD4-specific rates of death and tuberculosis among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa.

Access to Medicines: what should the industry contribute? Part II: Supply Chain & Delivery Systems - The Last Mile Challenge EFPIA 18 th September 2013.

ECONOMIC ASSESSMENT OF IMPLEMENTATION TREATMENT GUIDELINES OF HYPERTENSION IN OUT-PATIENT PRACTICE Kulmagambetov IR Karaganda State Medical Academy, Kazakhstan.

ILLEGAL DRUG STORES IN ZAMBIA PRESENTED BY A. PHIRI ARTHUR DAVISON CHILDREN’S HOSPITAL Presented to CSO workshop in Ndola on 29 August 2013.

Managing Medicines Use by PBC Groups in West Hertfordshire Dr Alison Davies.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Implications for Countries: Critical Issues in Service Delivery and Decision Making Dr. Yogan Pillay Deputy.

Managing depression in people with long term conditions Chris Dickens Professor of Psychological Medicine Peninsula College of Medicine and Dentistry.

Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.

“Who does provide services; and where? ” France: How we are moving medical abortion services away from hospital based Expanding Access to Medical Abortion:

Pharmacovigilance in public health programmes Author: Oscar O Simooya, Copperbelt University, Kitwe, Zambia Presented at the training course for introducing.

Human Capacity Development in Cote d’Ivoire: A Collaboration for Pre-Service Training in HIV, TB and Malaria between the Elizabeth Glaser Pediatric AIDS.

Prof. Dr. Christian Burri Head of Department Department of Medicines Research London, 6 th May 2014 Malaria - o n the road to malaria elimination? All-Party.

Funding Universal Access through a “Global Health Charge” on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics Dr Andrew.

The South African perspective

Use of an Indicator-Based System for Assessing, Monitoring, and Improving Pharmacy Practice Authors: Lates, J. (1); Sumbi, V. (2); Phulu, B. (1); Rushubiza,

Results of the Track 1.0 Antiretroviral Therapy Program February June 2007 Barbara Aranda-Naranjo, PhD, Director HIV/AIDS Bureau, Global HIV/AIDS.

Funding Universal Access through a “Global Health Charge” on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics Dr Andrew.

IRSS – Centre Muraz : A collaborative research initiative for the promotion of Health in Africa Maxime Koiné DRABO MD, MPH, PhD.

MALAWI GOVERNMENT MINISTRY OF HEALTH PROGRESS ON GOOD GOVERNANCE IN THE PHARMACEUTICAL SECTOR IN MALAWI By Dr Charles Mwansambo Secretary for Health 20.

Clinical trials in Madagascar : past and today Voahangy Rasolofo Unité des Mycobactéries Institut Pasteur de Madagascar "Ethical Issues in Clinical Trials"

WHO-HIV Department Strategic Information Unit AIDS Medicines and Diagnostics Service Contribution to Access to medicines Technical Briefing Seminar, November.

| Slide 1 of 25 April 2007 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Waterfront.

Dr Shanthi Pal Quality Assurance and Safety of Medicines WHO

Co-infections TB/HIV in prison Côte d’Ivoire Case study Doctor J-M MASUMBUKO ESTHER Coordinator in Côte d’ivoire 24 July th IAC,

Training course on the Pharmacovigilance of antiretroviral medicines 23 – 28 November 2009 Rationale, Objectives and Expected Outcomes.

The National HIV Counselling and Testing Campaign and Treatment Expansion in South Africa: A return on investments in combination prevention XIX International.

1 Partnering to Strengthen Local Efforts Can Help Us Get to Six Million on ART Anja Giphart, MD MPH Vice President, Program Implementation Elizabeth Glaser.

6 th Annual Emergency Plan for AIDS Relief Track 1.0 ART Program Meeting August 11–12, 2008; Washington D.C. Christian Pitter, MD MPH Director, Global.

International perspectives on human gene editing: South Africa KEYMANTHRI MOODLEY DIRECTOR & PROFESSOR CENTRE FOR MEDICAL ETHICS & LAW DEPARTMENT OF MEDICINE.

Operational research to Policy and Practice: examples Anthony D Harries, The Union, Paris, France London School Hygiene & Tropical medicine.

Mövenpick Royal Palm Hotel Dar es Salaam, Tanzania August 4-6, 2009 The 7th Annual Track 1.0 ART Program Meeting.

Dr Mary Couper Quality Assurance and Safety of Medicines WHO

HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.

Medicines Transparency Alliance02/02/ MeTA Peru Pedro Yarasca System of public information on prices of Pharmaceutical Products.

TBS Meeting Geneva, November 2010 Procurement and Supply Management Policies WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November.

Minimum requirements for Pharmacovigilance in countries.

DRUG USE PROFILES IN AN NGO-MANAGED HEALTH CENTRE VERSUS PRIVATE HEALTH PRACTITIONERS Mandal SC: Indian Pharmaceutical Association, Bengal Branch, Kolkata;

TANZANIA MAINLAND NATIONAL HEALTH POLICY AND STRATEGY REPORT.

HHS/CDC Track 1.0 Transition in Rwanda Dr Ida Kankindi, Rwanda Ministry of Health Dr Felix Kayigamba, CDC-Rwanda August

1 Innovative rapid scale-up of effective PMTCT services to achieve virtual elimination of new pediatric HIV infections: A Zimbabwe experience Dr. Agnes.

Improving HIV care and support service performance in Côte d’Ivoire M. N’goran 1 ; S. Ramachadran 2 ; J. Essombo 1 et al M. N’goran 1 ; S. Ramachadran.

Improving Patients Retention in Antiretroviral Treatment Programs: The experience of ARV Programs in Côte d’Ivoire Eugène MESSOU, MD, PhD CePReF- Aconda.

EGPAF GLOBAL: An Update on Transition Strategies & Implementation.

Taipei, June Content  Introduction about Vietnam’s Programmatic Management of Drug resistant Tuberculosis (PMDT) and drug resistant tuberculosis.

The Family AIDS Initiative: Scaling-up Family-Based Approaches to Care and Treatment in Cote d’Ivoire Joseph Essombo, Anthony Tanoh, Toure-Penda Diagola.

Electrotechnical Committee of Côte d’Ivoire (CELEC-CI)

Regional and country specific recommendations from macro-level private sector assessment Bettina Brunner Regional Manager, Francophone Africa, SHOPS.

11 viii. Develop capacity for signal detection and causality assessment Multi-partner training package on active TB drug safety monitoring and management.

The IMPRESS Health 2 project: Overview of Project Interventions

WHO Meeting of Interested Parties

CRESAC CONTRIBUTIONS TO THE IMPLEMENTATION OF WHO-AFRO STEPWISE LABORATORY QUALITY IMPROVEMENT PROCESS TOWARDS ACCREDITATION (SLIPTA) SCHEME IN COTE.

Abstract 28 Karen Webb, OPHID MOHCC/OPHID IAS 2017 Satellite Session

WHO minimum public health data set on prison health

Quality Assurance and Safety of Medicines

Dr Mahamat Hamid Ahmat SPECIALISTE EN SR

Thokozani Kalua MBBS MSc Malawi Ministry of Health

Ministry of Health Mozambique - Health Service Executive Ireland

The HIV Epidemic among People who Inject Drugs

Labour Standards in Quebec

Christine Halleux, MD, PhD

Medicines Safety Mary R. Couper

From TB control to integrated respiratory disease control

Background to ProTEST and its Role in TB/HIV Agenda-setting

Surveillance of Tuberculosis

Geneva, Switzerland June 2002

Quality Assurance and Safety of Medicines

Fabio Scano IUATLD Conference Paris, 2003

Pharmacovigilance.

Presentation transcript:

Dr Yao (WHO-CI) Dr N’Guessan-Irié (DPM) PHARMACOVILANCE ACTIVITIES IN CÔTE D’IVOIRE DELEGATION Dr Yao (WHO-CI) Dr N’Guessan-Irié (DPM)

PRESENTETION OF THE COUNTRY Côte d’Ivoire is a french speaking country in west Africa Area: 322.462 km2 Population: about 20 millions (1998) National level of HIV: 4.7% (higher in some areas) War in 2002 PNPEC = program in charge of people living with HIV SCMS, PEPFAR, CARE, EGPAF, Clinton Foundation …(ARV products suppliers)

INTRODUCTION No National Centre of Pharmacovigilance Pharmacovigilance supported by DPM (Direction de la Pharmacie et du Médicament) Project of a Pharmacovigilance Centre creation Project of Pharmacovigilance of ARVs in PNPEC

CURRENT ACTIVITIES of DPM Reception of reports from AFSSAPS and Pharmaceutical Plants Diffusion of informations to health practitioners Information of the Ministry in charge of health for decisions

PROJECT FOR THE CENTRE Identification of products adverse reactions in hospitals, chemist’ shops, program of specific diseases (HIV, TB, leprosy…) Studies of the different reports at the National Centre Answers of the Centre to those who notify Collaboration with international systems (UPSALA, AFSSAPS…) Form a database for further needs

CONCLUSION At present no Pharmacovigilance specific for ARV medicines The present workshop will contribute to implement pharmacovigilance of ARV medicines in our country

THANKYOU FOR PAYING ATTENTION